Wray, Sibyl <br/><br/>
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.  [electronic resource] 

 -  Multiple sclerosis (Houndmills, Basingstoke, England)  10 2019 
 - 1605-1617 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1477-0970 
<br/><br/><label>Standard No.: </label>10.1177/1352458518796675  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alemtuzumab--adverse effects<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Disease Susceptibility<br/>Female<br/>Humans<br/>Infections<br/>Interferon beta-1a--administration & dosage<br/>Male<br/>Multiple Sclerosis--drug therapy<br/>Recurrence<br/>Risk Factors<br/>Time Factors